Ariya Bio

Startup

We are developing gene therapies to treat hereditary blood disorders. Our lead project aims at curing Beta-Hemoglobinopathies which are the most common deadly monogenetic disorders worldwide with millions of affected individuals.The Beta-hemoglobinopathies are the most common monogenetic diseases worldwide with approximately 360,000 annual births with a serious form of the disease, and 7% of the world population being carriers. Current treatment options are limited, and no safe curative treatments exist. We are developing a one-time gene therapy that will reduce all disease symptoms in



website


Get Involved with the Advanced Therapies Congress

 

To sponsor or exhibit


Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032

 

 

To speak


Ila Dickinson
ila.dickinson@terrapinn.com
+44 207 092 1150